Aragen Life Sciences has filed draft papers with SEBI for an IPO consisting of a ₹800 crore fresh issue and an offer for sale. The company plans to use the proceeds primarily to repay debt and upgrade its research and manufacturing facilities. The firm provides contract research and manufacturing services to global pharmaceutical and biotech companies.
Aragen Life Sciences, a contract research, development, and manufacturing organization, has initiated its process to list on the stock exchanges. The company submitted its Draft Red Herring Prospectus (DRHP) to the Securities and Exchange Board of India (SEBI) on August 26, 2026. The proposed IPO comprises a fresh issue of equity shares worth up to ₹800 crore and an offer for sale (OFS) of over 2.73 crore shares by existing shareholders, including Goldman Sachs Capital Holdings.
For investors, the most significant aspect of this filing is how the company intends to use the capital. Aragen has explicitly stated that a primary goal is the repayment or pre-payment of existing debt, which should help improve its balance sheet strength and potentially reduce interest expenses. The remaining funds from the fresh issue are earmarked for capital expenditure, specifically to upgrade machinery at its primary facilities in Hyderabad and enhance infrastructure at the Bengaluru site owned by its subsidiary, Aragen Biologics.
Understanding the company’s scale is important for contextualizing this offer. In the fiscal year 2026, Aragen reported revenue of ₹2,178 crore with a profit of ₹258 crore. Since its founding in 2000, the company has operated as a partner to global pharmaceutical and biotechnology firms, managing tasks ranging from early-stage research to commercial production. As of March 2026, the company supported 591 global clients and employed over 4,300 people across several regions, including the United States, Europe, Japan, and the Asia-Pacific.
While the expansion plans and debt reduction are clear objectives, investors should also consider the inherent risks in the contract research sector. The company’s performance is closely linked to the global pharmaceutical industry’s R&D spending. Any slowdown in global R&D budgets or changes in outsourcing strategies by large pharmaceutical clients can directly impact Aragen’s revenue growth. Additionally, the company is undertaking significant capital expenditure. Scaling new facilities and upgrading current sites carries execution risks; if these projects face delays or do not achieve the expected efficiency gains, it could pressure profit margins.
The upcoming public issue will be managed by a group of financial institutions, including Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities, and JM Financial. Following this initial filing, market participants should watch for the regulator's observations, the final approval of the offer, the timeline for the issue, and the final pricing, which will determine the valuation at which the company seeks to list.